Department für Pharmazie Zi.Nr.: C1.050B |
Nuclear receptors like Nurr1 or RXR are promising targets in neurodegenerative diseases. My focus is on developing new ligands as tool compounds for these receptors. This will allow us to study the medicinal chemistry of these and their biological functions in a deeper way. In addition, I am investigating if there are still unknown endogenous ligands for nuclear receptors that have not been reported yet.
Sai, M.; Vietor, J.; Kornmayer, M.; Egner, M.; López-García, U.; Höfner, G.; Pabel, J.; Marschner, J.; Wein, T.; Merk, D. Structure-Guided Design of Nurr1 Agonists Derived from the Natural Ligand Dihydroxyindole. J. Med. Chem., 2023, DOI
Arifi,S; Becker, I.; Friedly, K.; Sai, M.; Zündorf,I.; Fürst, R. Ein “Trojanisches Pferd” als neue Therapieoption für lysosomale Speicherkrankheit. Pharmakon Arzneimittel in Wissenschaft und Praxis (DPhG), 2/2019, 7 Jg, 77-79.